Made available in DSpace on 2014-06-11T19:31:11Z (GMT). No. of bitstreams: 0 Previous issue date: 2008-12-18Bitstream added on 2014-06-13T19:20:17Z : No. of bitstreams: 1 gerardi_dg_dr_jabo.pdf: 906206 bytes, checksum: 29e6a477f11cbcccee68cc2a21495f1a (MD5) / Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) / Tendo em vista a expressão da proteína associada à resistência a múltiplas drogas (MRP1), da enzima glutationa-S-transferase pi (GSTpi) e da proteína p53 com o desenvolvimento da resistência a múltiplas drogas (RMD) nas células neoplásicas, objetivou-se neste estudo avaliar a expressão desses três marcadores, pela imunoistoquímica, em 68 espécimes de neoplasias caninas, incluindo tumores venéreos transmissíveis (TVTC), mastocitomas, carcinomas mamários e de glândula hepatóides e linfomas. Os espécimes foram subdivididos em: TVT, Tumor venéreo transmissível (n=9); TVTR, TVTs resistentes à quimioterapia (n=5); MASTI, mastocitomas cutâneos grau I (n=8); MASTIII, mastocitomas cutâneos grau III (n=8); CARM, carcinomas mamários (n=14); CARH, carcinomas de glândulas hepatóides (n=8); LINFB, linfomas de células B (n=9); LINFT, linfomas de células T (n=7). Resultados mostraram que as expressões da MRP1, GSTpi e p53 foram observadas em 38 (55%), 43 (62,3%) e 50 (72,4%) espécimes, respectivamente. Em 27 (39,1%) espécimes houve coexpressão dos três marcadores. A expressão da MRP1, GSTpi e p53 isoladas ou associadas pôde ser observada em todos os grupos experimentais, exceto o grupo TVTC que não expressou a MRP1. A localização da marcação nas células tumorais foi citoplasmática para MRP1 e nuclear e/ou citoplasmática para a GSTpi e p53. Não foi observada diferença na expressão dos marcadores de resistência a quimioterapia em relação à resistência a quimioterapia (TVT e TVTR), gradação histológica (MASTI e III) e imunofenótipo (LINFB e T). Há relação direta entre o aumento da expressão da MRP1 e da GSTpi nos linfomas T. / Multidrug resistance in tumors involves the expression of multidrug resistance protein-1 MRP1, enzyme glutathione-S-transferase pi (GSTpi), and p53 protein. Therefore, this study aimed at evaluating the expression of these three markers, by immunohistochemistry, in neoplasic cells. Sixty-eight canine tumor samples, including transmissible venereal tumor (TVTC), cutaneous mast cell tumor, mammary carcinoma, hepatoid gland carcinoma, and lymphoma were studied. Samples were assigned into one of the following subgroups: TVT, transmissible venereal tumor (n=9); TVTR, chemoresistant TVT (n=5), MASTI, grade-I cutaneous mast cell tumor (n=8); MASTIII, grade-III cutaneous mast cell tumor (n=8); CARM, mammary carcinoma (n=14); CARH, hepatoid gland carcinoma (n=8); LINFB, B-cell lymphoma (n=9); LINFT, T-cell lymphoma (n=7). We observed that 38 (55%), 43 (62.3%), and 50 (72.4%) samples expressed MRP1, GSTpi, and p53, respectively. Co-expression of the three markers was present in 27 (39.1%) samples. Expression of MRP1, GSTpi, and p53 alone or associated could be observed in all experimental groups, except for TVT group which did not express MRP1. Staining in the tumor cells was cytoplasmatic to MRP1, and both nuclear and cytoplasmatic to GSTpi and p53. No significant difference in the expression of the markers could be observed with relation to chemoresistance (TVT and TVTR), histological grade (MASTI and MASTIII) and immunophenotype (LINFB and LINFT). A direct relation was present between the raise of the expression of MRP1 and GSTpi in T cells lymphoma.

Orientadora: Mirela Tinucci Costa / Banca: Renée Laufer Amorim / Banca: Carlos Roberto Daleck / Banca: Felipe Augusto Ruiz Sueiro / Banca: Noeme Sousa Rocha / Resumo: Tendo em vista a expressão da proteína associada à resistência a múltiplas drogas (MRP1), da enzima glutationa-S-transferase pi (GSTpi) e da proteína p53 com o desenvolvimento da resistência a múltiplas drogas (RMD) nas células neoplásicas, objetivou-se neste estudo avaliar a expressão desses três marcadores, pela imunoistoquímica, em 68 espécimes de neoplasias caninas, incluindo tumores venéreos transmissíveis (TVTC), mastocitomas, carcinomas mamários e de glândula hepatóides e linfomas. Os espécimes foram subdivididos em: TVT, Tumor venéreo transmissível (n=9); TVTR, TVTs resistentes à quimioterapia (n=5); MASTI, mastocitomas cutâneos grau I (n=8); MASTIII, mastocitomas cutâneos grau III (n=8); CARM, carcinomas mamários (n=14); CARH, carcinomas de glândulas hepatóides (n=8); LINFB, linfomas de células B (n=9); LINFT, linfomas de células T (n=7). Resultados mostraram que as expressões da MRP1, GSTpi e p53 foram observadas em 38 (55%), 43 (62,3%) e 50 (72,4%) espécimes, respectivamente. Em 27 (39,1%) espécimes houve coexpressão dos três marcadores. A expressão da MRP1, GSTpi e p53 isoladas ou associadas pôde ser observada em todos os grupos experimentais, exceto o grupo TVTC que não expressou a MRP1. A localização da marcação nas células tumorais foi citoplasmática para MRP1 e nuclear e/ou citoplasmática para a GSTpi e p53. Não foi observada diferença na expressão dos marcadores de resistência a quimioterapia em relação à resistência a quimioterapia (TVT e TVTR), gradação histológica (MASTI e III) e imunofenótipo (LINFB e T). Há relação direta entre o aumento da expressão da MRP1 e da GSTpi nos linfomas T. / Abstract: Multidrug resistance in tumors involves the expression of multidrug resistance protein-1 MRP1, enzyme glutathione-S-transferase pi (GSTpi), and p53 protein. Therefore, this study aimed at evaluating the expression of these three markers, by immunohistochemistry, in neoplasic cells. Sixty-eight canine tumor samples, including transmissible venereal tumor (TVTC), cutaneous mast cell tumor, mammary carcinoma, hepatoid gland carcinoma, and lymphoma were studied. Samples were assigned into one of the following subgroups: TVT, transmissible venereal tumor (n=9); TVTR, chemoresistant TVT (n=5), MASTI, grade-I cutaneous mast cell tumor (n=8); MASTIII, grade-III cutaneous mast cell tumor (n=8); CARM, mammary carcinoma (n=14); CARH, hepatoid gland carcinoma (n=8); LINFB, B-cell lymphoma (n=9); LINFT, T-cell lymphoma (n=7). We observed that 38 (55%), 43 (62.3%), and 50 (72.4%) samples expressed MRP1, GSTpi, and p53, respectively. Co-expression of the three markers was present in 27 (39.1%) samples. Expression of MRP1, GSTpi, and p53 alone or associated could be observed in all experimental groups, except for TVT group which did not express MRP1. Staining in the tumor cells was cytoplasmatic to MRP1, and both nuclear and cytoplasmatic to GSTpi and p53. No significant difference in the expression of the markers could be observed with relation to chemoresistance (TVT and TVTR), histological grade (MASTI and MASTIII) and immunophenotype (LINFB and LINFT). A direct relation was present between the raise of the expression of MRP1 and GSTpi in T cells lymphoma. / Doutor

Nuclear receptors play significant roles in the regulation of transporters and enzymes to balance the level of endogenous molecules and to protect the body from foreign molecules. The vitamin D receptor (VDR) and its natural ligand, 1alpha,25-dihydroxyvitamin D3 [1,25(OH)2D3], was shown to upregulate rat ileal apical sodium dependent bile acid transporter (Asbt) to increase the reclamation of bile acids, ligands of the farnesoid X receptor (FXR). FXR is considered to be an important, negative regulator of the cholesterol metabolizing enzyme, Cyp7a1, which metabolizes cholesterol to bile acids in the liver. In rats, decreased Cyp7a1 and increased P-glycoprotein/multidrug resistance protein 1 (P-gp/Mdr1) expressions pursuant to 1,25(OH)2D3 treatment was viewed as FXR effects in which hepatic VDR protein is poorly expressed. In contrast, changes in rat intestinal and renal transporters such as multidrug resistance associated proteins (Mrp2, Mrp3, and Mrp4), Asbt, and P-gp after administration of 1,25(OH)2D3 were attributed directly as VDR effects due to higher VDR levels expressed in these tissues. Higher VDR expressions were found among mouse hepatocytes compared to those in rats. Hence, fxr(-/-) and fxr(+/+) mouse models were used to discriminate between VDR vs. FXR effects in murine livers. Hepatic Cyp7a1 in mice was found to be upregulated with 1,25(OH)2D3 treatment, via the derepression of the short heterodimer partner (SHP). Putative VDREs, identified in mouse and human SHP promoters, were responsible for the inhibitory effect on SHP. The increase in hepatic Cyp7a1 expression and decreased plasma and liver cholesterol were observed in mice prefed with a Western diet. A strong correlation was found between tissue Cyp7a1 and P-gp changes and 1,25(OH)2D3 plasma and tissue concentrations, confirming that VDR plays an important role in the disposition of xenobiotics and cholesterol metabolism. Moreover, renal and brain Mdr1a/P-gp were found to be directly upregulated by the VDR in mice, and concomitantly, increased renal and brain secretion of digoxin, a P-gp substrate, in vivo. The important observations: the cholesterol lowering and increased brain P-gp efflux activity properties suggest that VDR is a therapeutic target for treatment of hypercholesterolemia and Alzheimer’s diseases, since beta amyloid, precursors of plague, are P-gp substrates.

Nuclear receptors play significant roles in the regulation of transporters and enzymes to balance the level of endogenous molecules and to protect the body from foreign molecules. The vitamin D receptor (VDR) and its natural ligand, 1alpha,25-dihydroxyvitamin D3 [1,25(OH)2D3], was shown to upregulate rat ileal apical sodium dependent bile acid transporter (Asbt) to increase the reclamation of bile acids, ligands of the farnesoid X receptor (FXR). FXR is considered to be an important, negative regulator of the cholesterol metabolizing enzyme, Cyp7a1, which metabolizes cholesterol to bile acids in the liver. In rats, decreased Cyp7a1 and increased P-glycoprotein/multidrug resistance protein 1 (P-gp/Mdr1) expressions pursuant to 1,25(OH)2D3 treatment was viewed as FXR effects in which hepatic VDR protein is poorly expressed. In contrast, changes in rat intestinal and renal transporters such as multidrug resistance associated proteins (Mrp2, Mrp3, and Mrp4), Asbt, and P-gp after administration of 1,25(OH)2D3 were attributed directly as VDR effects due to higher VDR levels expressed in these tissues. Higher VDR expressions were found among mouse hepatocytes compared to those in rats. Hence, fxr(-/-) and fxr(+/+) mouse models were used to discriminate between VDR vs. FXR effects in murine livers. Hepatic Cyp7a1 in mice was found to be upregulated with 1,25(OH)2D3 treatment, via the derepression of the short heterodimer partner (SHP). Putative VDREs, identified in mouse and human SHP promoters, were responsible for the inhibitory effect on SHP. The increase in hepatic Cyp7a1 expression and decreased plasma and liver cholesterol were observed in mice prefed with a Western diet. A strong correlation was found between tissue Cyp7a1 and P-gp changes and 1,25(OH)2D3 plasma and tissue concentrations, confirming that VDR plays an important role in the disposition of xenobiotics and cholesterol metabolism. Moreover, renal and brain Mdr1a/P-gp were found to be directly upregulated by the VDR in mice, and concomitantly, increased renal and brain secretion of digoxin, a P-gp substrate, in vivo. The important observations: the cholesterol lowering and increased brain P-gp efflux activity properties suggest that VDR is a therapeutic target for treatment of hypercholesterolemia and Alzheimer’s diseases, since beta amyloid, precursors of plague, are P-gp substrates.